<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971526</url>
  </required_header>
  <id_info>
    <org_study_id>29426989</org_study_id>
    <nct_id>NCT03971526</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke</brief_title>
  <official_title>Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a New Highly Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic resonance imaging (MRI) is the diagnostic cornerstone for precisely identifying
      acute ischaemic strokes and locating vascular occlusions.

      It was observed that a post-contrast three-dimensional turbo-spin-echo T1weighted sequence
      showed striking post-contrast vascular hyperintensities (PCVH) in ischaemic territories. The
      aim is to evaluate the prevalence and the meaning of this finding.

      This study included 130 consecutive patients admitted for acute ischaemic stroke with a 3-T
      MRI performed in the first 12 h of symptom onset from September 2014 through September 2016.
      Two neuroradiologists blinded to clinical data analysed the first MRI assessments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Actual">September 1, 2016</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overal survival</measure>
    <time_frame>7 years</time_frame>
    <description>from the AR-PML diagnosis date to that of death or censored on 31 December 2015</description>
  </primary_outcome>
  <enrollment type="Actual">130</enrollment>
  <condition>Acute Ischaemic Stroke</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI images review</intervention_name>
    <description>MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        130 consecutive patients admitted for acute ischaemic stroke with a 3-T MRI performed in
        the first 12 h of symptom onset.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients aged 18 and older at onset of an acute ischaemic stroke

          -  Availability of at least one pre-therapeutic MRI performed in our centre within 12 h
             of stroke onset, including a post-contrast 3D TSE T1-weighted sequence.

        Exclusion criteria:

          -  Patients with posterior fossa strokes

          -  Patients with known intracranial vasculitis or MoyaMoya disease

          -  Presence of severe MR imaging artefacts preventing correct interpretation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrovascular disorders</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Neuroimaging</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

